Displaying 13 - 24 of 42
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
6

Mirum: PSC and IBAT Inhibitors: Can We Apply Our Paediatric Experience in Adult Hepatology? - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Displaying 13 - 24 of 42